Company intelligence / Profile preview

Epoch Biodesign

London, England, United Kingdomepochbiodesign.com ↗

Ownership: Private
Employees: ~32
Development stage: Other

Overview

Epoch Biodesign has developed a proprietary biorecycling platform using AI-designed enzymes capable of breaking down previously unrecyclable plastics such as nylon and polyester at low temperatures. Their approach enables circularity by converting waste into valuable chemicals used in apparel, automotive, packaging, and other industries. They have demonstrated successful pilot projects and established over 40 industry partnerships to advance commercialization.

Modalities: EnzymeRecombinant protein
Industry: Non-Drug Biotech

Partnerships

Inditex (multi-year joint development agreement on nylon recycling)

Beyond the preview

Go deeper on Epoch Biodesign.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epoch Biodesign.

Explore the full profile